Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Accured Expenses (2016 - 2025)

Cumberland Pharmaceuticals' Change in Accured Expenses history spans 16 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 2580.43% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $6.7 million, up 776.77%, while the annual FY2025 figure was $6.7 million, 776.77% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $8.0 million at Cumberland Pharmaceuticals, up from $684224.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.0 million in Q4 2025 and bottomed at -$1.7 million in Q2 2021.
  • The 5-year median for Change in Accured Expenses is $134727.0 (2021), against an average of $1.1 million.
  • The largest annual shift saw Change in Accured Expenses tumbled 135.3% in 2021 before it skyrocketed 2957.92% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.1 million in 2021, then soared by 172.09% to $5.8 million in 2022, then tumbled by 119.2% to -$1.1 million in 2023, then skyrocketed by 70.66% to -$324294.0 in 2024, then surged by 2580.43% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Change in Accured Expenses are $8.0 million (Q4 2025), $684224.0 (Q3 2025), and -$1.4 million (Q2 2025).